A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.

about

A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.

Item

http://www.wikidata.org/entity/Q41652561

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

A phase I pharmacodynamic stud ...... ornia Cancer Consortium study.

@en

type

Item

label

A phase I pharmacodynamic stud ...... ornia Cancer Consortium study.

@en

prefLabel

A phase I pharmacodynamic stud ...... ornia Cancer Consortium study.

@en

P1476

A phase I pharmacodynamic stud ...... ornia Cancer Consortium study.

@en

P2093

Edward M Newman

http://www.w3.org/2001/XMLSchema#string

Joseph M Tuscano

http://www.w3.org/2001/XMLSchema#string

Kenneth K Chan

http://www.w3.org/2001/XMLSchema#string

Leslie Popplewell

http://www.w3.org/2001/XMLSchema#string

Mark H Kirschbaum

http://www.w3.org/2001/XMLSchema#string

Omar Aljitawi

http://www.w3.org/2001/XMLSchema#string

Paul Frankel

http://www.w3.org/2001/XMLSchema#string

Robert Chen

http://www.w3.org/2001/XMLSchema#string

Yun Yen

http://www.w3.org/2001/XMLSchema#string

Zhiliang Xie

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.

Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.

Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.

An overview of the clinical experience with hydroxyurea.

Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase.

Ribonucleotide reductase inhibitors and future drug design.

The RR1 gene of herpes simplex virus type 1 is uniquely trans activated by ICP0 during infection.

Structure and promoter characterization of the gene encoding the large subunit (R1 protein) of mouse ribonucleotide reductase

A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.

Enhanced malignant transformation induced by expression of a distinct protein domain of ribonucleotide reductase large subunit from herpes simplex virus type 2.

P304

2307-2314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2016.1146947

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Timothy Synold

P577

2016-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26895565

http://www.w3.org/2001/XMLSchema#string

P921

California

P932

4969190

http://www.w3.org/2001/XMLSchema#string